Last reviewed · How we verify
Loceryl NL
Loceryl is an antifungal nail lacquer that inhibits fungal cell wall synthesis by disrupting ergosterol production.
Loceryl is an antifungal nail lacquer that inhibits fungal cell wall synthesis by disrupting ergosterol production. Used for Onychomycosis (fungal nail infection).
At a glance
| Generic name | Loceryl NL |
|---|---|
| Also known as | Loceryl Nail Lacquer |
| Sponsor | Galderma R&D |
| Drug class | Antifungal (morpholine derivative) |
| Target | Fungal sterol synthesis enzymes (Δ14-reductase, Δ8-Δ7-isomerase) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Amorolfine, the active ingredient in Loceryl, is a morpholine antifungal that inhibits sterol 14α-demethylase, a key enzyme in fungal ergosterol biosynthesis. By disrupting ergosterol production, the drug compromises fungal cell membrane integrity, leading to fungal cell death. It is applied topically as a nail lacquer for direct delivery to infected nail tissue.
Approved indications
- Onychomycosis (fungal nail infection)
Common side effects
- Nail discoloration
- Nail brittleness
- Local irritation at application site
- Periungual erythema
Key clinical trials
- Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish (PHASE4)
- Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer (PHASE4)
- Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Loceryl NL CI brief — competitive landscape report
- Loceryl NL updates RSS · CI watch RSS
- Galderma R&D portfolio CI